

## AMENDMENTS TO THE SPECIFICATION

### In the specification:

Please replace the paragraph on page 1 under the title with the following paragraph:

#### --Cross-References To Related Applications

This application is a divisional of Application No. 08/812,383, filed March 5, 1997, now abandoned, which claims priority of U.S. Provisional Application 60/012,845, filed March 5, 1996.--

Please replace the paragraph on page 8, lines 1-15, with the following paragraph:

--Briefly, four types of chimeric molecules were constructed: two are the dimers obtained as  $\alpha/\zeta$  + the  $\beta/\zeta$  and two are single-chain TCR/ $\zeta$  chimeric molecules analogous to those shown in Figure 1 herein. The complete nucleotide sequence encoding the single chain form with the CD8 hinge is shown in Figures 3A-3B~~Figures 3A-3D~~. These four constructs were transfected into the T cell hybridoma MD.45-27 and the transformants were grown under neomycin selection and screened for IL-2 secretion upon stimulation with either spleen cells from Balb/c or P815(H-2<sup>d</sup>) cells pulsed with the HA-specific peptide or RENCA tumor cell line transfected with the HA gene. The results showing the levels of IL-2 produced are shown in Figure 4. As shown, none of the transfectants showed appreciable production of IL-2 in the absence of HA. Only the transfectants containing the clone 4 derivatives showed stimulation of IL-2 production when HA was present. Both single-chain forms, with and, without the CD8

hinge and both dimeric forms, both with and without the CD8 hinge showed appreciable stimulation of IL-2 production when treated either with Balb/c spleen cells plus HA peptide, P815 cells plus HA peptide, or RENCA cells expressing HA at their surfaces.--